Last reviewed · How we verify
NCT06971107
Current Microsatellite Stability Results in Colon Cancer
trial in Colon Adenocarcinoma in 1,500 participants. Not yet recruiting.
31 May 2026
Quick facts
| Lead sponsor | Turkish Society of Colon and Rectal Surgery |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 1,500 |
| Start date | 1 June 2025 |
| Primary completion | 31 May 2026 |
| Estimated completion | 31 May 2029 |
| Sites | 2 locations across Turkey (Türkiye) |
Conditions studied
- Colon Adenocarcinoma — all drugs for Colon Adenocarcinoma →
- MSI Positive Colorectal Cancer — all drugs for MSI Positive Colorectal Cancer →
- MSI Negative Colorectal Cancer — all drugs for MSI Negative Colorectal Cancer →
Sponsor
Turkish Society of Colon and Rectal Surgery
Who can join
18 and older, any sex, with Colon Adenocarcinoma or MSI Positive Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this prospective observational study is to learn more about how a specific type of DNA repair issue-called mismatch repair deficiency (dMMR)-affects colon cancer in people living in Turkey. The study will look at how often dMMR occurs, how it is reported, and how it relates to treatment outcomes. The main questions it aims to answer are: * How common is dMMR in colon cancer, and does it vary by where the tumor is in the colon? * How often is MSI (microsatellite instability) status reported in colon cancer biopsy reports before surgery? * How do different types of dMMR (such as MLH1/PMS2 loss, MSH2/MSH6 loss, or sporadic cases) affect survival over three years? Participants will: * Be people who had surgery for colon cancer between June 1, 2025 and May 31, 2026 at hospitals in Turkey that treat more than 30 colon cancer cases each year. * Have their medical and pathology data reviewed, including information about tumor location, biopsy results, surgery, and treatment. This study will not involve any new treatments. Instead, it will use existing medical records to better understand how to improve care and identify people who may benefit from immunotherapy. Results from this study will be shared at scientific meetings and published in medical journals.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06971107
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colon Adenocarcinoma
Currently open trials in the same condition.
- NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
- NCT06997497 — A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-108 · Phase 3 · recruiting
- NCT06652672 — Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma · NA · recruiting
- NCT06709885 — HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer · Phase 2 · recruiting
- NCT06640166 — Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Co · Phase 2 · recruiting
Other Turkish Society of Colon and Rectal Surgery trials
Trials by the same sponsor.
- NCT06823297 — Can Neoadjuvant Chemoradiotherapy be Ommited in Mid-rectal Cancer · not yet recruiting
- NCT06902701 — Endoscopic Submucosal Dissection vs. Transanal Endoscopic Surgery for Rectal Neoplasia · not yet recruiting
- NCT06984601 — RELIEF Study: Resolving Fissures With Lateral Internal Sphincterotomy · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06971107 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Turkish Society of Colon and Rectal Surgery
- Last refreshed: 14 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06971107.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing